Kaleido Biosciences

Kaleido Biosciences is a clinical-stage biotechnology company that is developing the first therapeutic products to systematically shape the microbiome. The human microbiome is one of the most important frontiers in modern medicine. It plays a central role in numerous severe metabolic, inflammatory, and infectious diseases. Kaleido has discovered a broad new means of driving the central functions of the human microbiome with applications spanning a wide range of important diseases.


Company Profile

Kaleido Biosciences Logo

Flagship Partners:

  • Geoffrey von Maltzahn, Partner
  • Noubar Afeyan, Founder & CEO